



COMBINED GENERAL MEETING JUNE 25, 2026

Company's Board of Directors and general management

**Including the information required pursuant to
Article R. 225-83, 5° of the French Commercial Code,
in connection with proposals for the appointment or
reappointment of Directors**

This document includes translated excerpts, into English, of Section 2 of the Company's 2025 Universal Registration Document. The Company's 2025 Universal Registration Document is available in its entirety in the French language at the following address: <https://valneva.com/investors/financial-reports/>.

In case of discrepancy between the French and the English version, the French version shall prevail.



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.

VALNEVA

A European company (*Societas Europaea* or SE) with a Board of Directors

Share capital: €28,465,685.55

Registered office: Îlot Saint-Joseph, Bureaux Convergence, Bât. A, 12 ter Quai Perrache, 69002 Lyon (France)

Lyon Companies Register (RCS) No. 422 497 560

COMPANY'S BOARD OF DIRECTORS AND GENERAL MANAGEMENT

(INCLUDING THE INFORMATION REQUIRED
PURSUANT TO ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE,
IN CONNECTION WITH PROPOSALS FOR THE APPOINTMENT OR REAPPOINTMENT OF DIRECTORS)

1. BOARD OF DIRECTORS

The Company's Board of Directors is currently composed of the following members:

- Ms. Anne-Marie Graffin, Chair of the Board of Directors;
- Mr. James Sulat, Vice-Chair of the Board of Directors;
- Mr. James Connolly, member of the Board of Directors;
- Mr. Gerd Zettlmeissl, member of the Board of Directors;
- Ms. Danièle Guyot-Caparros, member of the Board of Directors;
- Ms. Kathrin Jansen, member of the Board of Directors; and
- Mr. Thomas Lingelbach, member of the Board of Directors and CEO (*Directeur Général*).

It is proposed to the shareholders of this Combined General Meeting:

- to reappoint, as Company Directors, Ms. Anne-Marie Graffin, Mr. James Sulat and Ms. Kathrin Jansen, for a one-year (1) term expiring at the end of the General Meeting to be called in 2027 to approve the financial statements for the fiscal year ending December 31, 2026;
- to reappoint, as a Company Director, Mr. James Connolly, for a two-year (2) term expiring at the end of the General Meeting to be called in 2028 to approve the financial statements for the fiscal year ending December 31, 2027; and
- to reappoint, as a Company Director, Mr. Thomas Lingelbach, for a three-year (3) term expiring at the end of the General Meeting to be called in 2029 to approve the financial statements for the fiscal year ending December 31, 2028.



Ms. Anne-Marie Graffin
CHAIR OF VALNEVA SE'S BOARD OF DIRECTORS
 ([65] YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since July 5, 2013)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (Eliminated in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	—	Member since December 17, 2024; (previously Chair, from December 20, 2023)	—	—	Experience as an executive in the vaccine industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Vetoquinol SA^(*)

- Board member, since September 2022

Sartorius Stedim Biotech SA^(*)

- Board member, since April 2015

Nanobiotix SA^(*)

- Supervisory Board member, since January 2014

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

M2Care SAS

- Board member, from October 2019 to June 2022

SMAG Consulting SAS

(formerly SARL SMAG Consulting)

- President, from April 2021 to October 2024, (previously Managing Director of the SARL, since September 2011)

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

(1) Current listed companies are indicated by (*).

Biography

Ms. Anne-Marie Graffin, a French national, served as Chief Executive Officer of the Big Booster Acceleration Program, an international non-profit acceleration program for startups, from 2011 to May 2017. Prior to that, she served in a variety of positions, most recently as Executive Vice President and member of the Executive Committee at Sanofi Pasteur MSD, a European vaccine company, from 1998 to 2011. Ms. Graffin has served on the Supervisory Board of Nanobiotix S.A. (Nasdaq: NBTX) since January 2014, on the board of Sartorius Stedim Biotech SA since April 2015, and on the Board of Directors of Vetoquinol SA since 2022. Ms. Graffin received her MBA from ESSEC Business School Paris.



Mr. James Sulat
VICE-CHAIR OF VALNEVA SE'S BOARD OF DIRECTORS
(75 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously Vice-Chair of the Company's Supervisory Board since May 28, 2013)
End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (Eliminated in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Member since September 25, 2024; (previously Chair, since December 20, 2023)	Member from December 2023 to June 2025	—	—	Finance, Strategy, Capital Markets and Corporate Governance

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW
 —

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES
 —

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW
 —

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

- GS Holdings, Inc.**
 - Member of the Board of Directors, from October 2021 to December 2025
- Mallinckrodt pic^(*)**
 - Member of the Board of Directors, from June 2022 to November 2023
 - Chair of the Audit Committee, from June 2022 to November 2023
 - Member of the Compensation Committee, from June 2022 to November 2023
- Excicure, Inc.^(*)**
 - Member of the Board of Directors, from January 2021 to December 2022
 - Chair of the Audit Committee, from January 2021 to December 2022
- Arch Therapeutics, Inc.**
 - Member of the Board of Directors, from August 2015 to December 2021

(1) Current listed companies are indicated by (*).

Biography

Mr. James Sulat, an American national, served on the Supervisory Board of Intercell AG from 2005 until its merger with Vivalis SA in 2013. From 2005 to 2009, Mr. Sulat served in a variety of roles at Memory Pharmaceuticals Corp., including as President and Chief Executive Officer from 2005 to 2008 and as a member of Memory's Board of Directors from 2005 to 2009. Previously, Mr. Sulat served as Chief Financial Officer for Chiron Corporation and Stanford Health Services. From 2009 to 2013, Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., and as a member of Maxygen's Board of Directors from 2003 to 2013. He previously served on the Board of Directors of GS Holdings, Inc. from 2021 to 2025, on the Board of Directors of Mallinckrodt pic, from 2022 to 2023, on the Board of Directors of Excicure, Inc., from 2021 until December 2022 and on the Board of Directors of Arch Therapeutics, Inc. from 2015 until December 2021. Mr. Sulat received an MBA and an M.S. in Health Services Administration from Stanford University and a B.S. in Administrative Sciences from Yale University.

2 Corporate Governance

Composition and governing rules of the administrative and management bodies



Mr. James Connolly
MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS
(61 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since June 23, 2022)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (Eliminated in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Member since December 20, 2023	Chair since December 17, 2024 (and member since December 20, 2023)	—	—	Commercial/ Marketing, Corporate Strategy, Finance, Business Development and Corporate Governance

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

IAVI

- Member of the Board of Directors, since October 2018

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Covenant House Pennsylvania

- Member of the Board of Directors, from November 2013 to September 2023

Ambulatus Robotics Inc.

- Member of the Board of Directors, from September 2020 to December 2021

(1) Current listed companies are indicated by (*).

Biography

Mr. James Edward Connolly, an American national, holds a B.S.B.A. from Washington University in St Louis. Since 2013, Mr. Connolly has been providing broad based consulting and advisory services to a variety of vaccine, biopharmaceutical and investment organizations. From 2010 to 2013, Mr. Connolly was President and CEO of Aeras (now IAVI). Prior to this, he spent 24 years at Wyeth (now Pfizer) in a series of increasingly senior roles, including Executive Vice President and General Manager, Wyeth Vaccines and President, Wyeth Canada. He previously served on the Board of Directors of Vaxess Technologies (2013-2019), Aeras (2013-2018), PaxVax (2014-2018) and Ambulatus Robotics (2020-2021). Mr. Connolly currently serves on the Board of Directors of IAVI.



Ms. Kathrin Jansen
MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS
(68 ANS)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since June 21, 2023)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (Eliminated in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	—	—	Member from December 2023 to June 2025	Chair since December 20, 2023	More than three decades of vaccine R&D experience

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

ReIGNITE Therapeutics

- Member of the Board of Directors, *since January 2024*
- Special Scientific Advisor, *since January 2024*

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Pfizer Inc.^(*)

- Senior Vice President and Head of Vaccine Research and Development, *from June 2015 to July 2022*

OTHER POSITIONS

VaxCo

- Scientific Advisor, *since January 2024*

Bill & Melinda Gates Foundation

- Scientific Advisor, *since December 2023*

Wistar Institute

- Strategic Advisor to the Director of the Vaccine and Immunotherapy Center, *since January 2023*

Pfizer Inc.^(*)

- Consultant, *since September 2022*

(1) Current listed companies are indicated by (*).

Biography

Ms. Kathrin U. Jansen, a German national, has over 30 years of vaccine R&D experience focused on the development of vaccines addressing large unmet medical needs. From 2015 to 2022 she served as Senior Vice President and Head of Vaccine Research and Development at Pfizer Inc, and as a member of Pfizer's Worldwide Research, Development and Medical leadership team. She led a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to clinical development, registration, and post marketing commitments of all of Pfizer's vaccines, including partnered ones. Most notably she led the development of several highly successful and licensed vaccines such as Pfizer/BioNtech's SARS-CoV-2 (COMINARTY), the first-ever licensed mRNA vaccine, Pfizer's *Streptococcus pneumoniae* (Pvnaer 20), Respiratory syncytial virus (Abrysvo), and Meningococcal B Group B (Trumenba) vaccines. From 2006 to 2015, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and then Pfizer and was responsible for vaccine discovery, early development, and clinical testing operations. Prior to Wyeth, Dr. Jansen spent 12 years at Merck Research Laboratories supporting several vaccine efforts and leading the R&D activities of Gardasil, the world's first cervical cancer vaccine. Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania School of Medicine in 2010 and has authored and co-authored over 200 publications. She is a member of the National Academy of Medicine, National Academy of Engineering, a Fellow of the Royal Society of Medicine and recipient of the Albert E Sabin Gold Medal. Dr. Jansen received her Ph.D. in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany, in 1984 followed by postdoctoral training at Cornell University.



Ms. Danièle Guyot-Caparros

MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS
(67 ANS)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on June 26, 2024

End of current term of office at the end of the General Meeting called in 2027 to approve the annual financial statements of the fiscal year ending on December 31, 2026

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (Eliminated in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Chair since September 25, 2024 (and member since June 26, 2024)	—	—	—	Experience in the field of finance and commercial operations

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

ALTEN Group^(*)

- Member of the Board of Directors (*Administratrice indépendante*), since October 2025
- Chair of the Audit Committee (*Présidente du Comité d'audit*), since October 2025

DBV Technologies^(*)

- Member of the Board of Directors (*Administratrice indépendante*), since October 2022
- Member of the Audit and Compensation Committee, since October 2022

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Onxeo (Valerio Therapeutics)^(*)

- Member of the Board of Directors (*Administratrice indépendante*) from July 2013 to July 2022

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

(1) Current listed companies are indicated by (*).

Biography

Danièle Guyot-Caparros, a French national, started her career in Audit and Corporate Finance with PWC specializing in the Chemical/Pharma Industry. In 1992, she joined Rhône-Poulenc-Rorer (later Aventis and Sanofi) where she held several senior finance positions (CFO Global R&D, CFO Europe, Group Planning). In 2008, she became Senior Advisor for Deloitte France to support the development of the Life Sciences and Health Care Industry practice. She has supported multiple engagements with a large diversity of clients (big and mid-size pharma companies, biotech, foundations etc.) focusing on transformation, governance issues and M&A. Ms. Guyot-Caparros is also an experienced non-executive director with a focus on Biotech/Medtech. From 2015 to 2017, she was board and Audit Committee member at Diaxonhit (now Eurobio Scientific) listed on Euronext Growth. She chaired the Audit Committee of Supersonic Imagine from July 2018 to September 2019 until the acquisition of the company by US group Hologic. From 2013 to June 2022, she chaired the Audit Committee of ONXEO (listed on Euronext, OMX Copenhagen and now Euronext Growth) and chaired the board from May 2019 to July 2021. In October 2022, she joined the board of DBV Technologies, a company listed on Euronext and Nasdaq, and is a member of the Audit Committee and of the compensation committee. Ms. Guyot-Caparros is a graduate from ICN (Institut Commercial de Nancy), with specialization in finance and accounting. She holds a chartered accountant degree and a non-executive director qualification awarded by IFA-Sciences-Po.



Mr. Thomas Lingelbach

**MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS - CEO (DIRECTEUR GÉNÉRAL)
(62 YEARS OLD)**

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously Chair of the Company's Management Board since May 28, 2013)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (The committee ceased to exist in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
No	—	—	Chair from December 2023 to June 2025	Member since December 20, 2023	More than 30 years of experience in the vaccine industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

VBC 3 Errichtungs GmbH

- Geschäftsführer, since October 2023

Valneva UK Limited

- Director, since October 2015

Valneva Sweden AB

- Chair of the Board, since February 2015

Valneva Canada Inc.

- Director, since January 2015

Vaccines Holdings Sweden AB

- Chair of the Board, since December 2014

Valneva Austria GmbH

- Geschäftsführer, since August 2013

Valneva USA Inc.

- CEO, since November 2012
- Director, since August 2008

Valneva Scotland Ltd.

- Director, since December 2006

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- Supervisory Board member, from February 2019 to August 2024

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

(1) Current listed companies are indicated by (*).

Biography

Mr. Thomas Lingelbach, a German national, was CEO of Intercell AG and is the founding President and CEO of Valneva. He is an established vaccine industry leader with broad experience. Prior to joining Intercell, he served as Vice President and Executive Committee Member, Global Vaccines Industrial Operations for Chiron Corporation. Upon Chiron's acquisition by Novartis, he served as General Manager and Managing Director of Novartis Vaccines & Diagnostics GmbH & Co KG. During his more than 30 years in vaccines, he held a variety of positions from product development to commercialization, with a strong emphasis on technical development and operations. In different capacities, he contributed to the successful development and licensure of more than ten novel vaccines. Mr. Lingelbach holds an M.S. in Engineering from *Technische Hochschule Mittelhessen (THM)*, specialized in bioprocess engineering and complemented his education with a business administration program.



Mr. Gerd Zettlmeissl

MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS
(70 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on June 25, 2025

End of current term of office at the end of the General Meeting called in 2028 to approve the annual financial statements of the fiscal year ending December 31, 2027

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE (Eliminated in June 2025)	SCIENCE AND TECHNOLOGY COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	—	Member since June 25, 2025	—	Member since June 25, 2025	More than 30 years of experience in the biopharmaceutical industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (in the last five years)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

MinervaX ApS

- Chairman of the Supervisory Board (*Président du conseil de surveillance*), from October 2021 to November 2024

Hilleman Laboratories

- Chairman and member of the Supervisory Board (*Président et membre du conseil de surveillance*), from September 2013 to August 2023

Medigene AG

- Chairman and member of the Supervisory Board (*Président et membre du conseil de surveillance*), from September 2013 to August 2023

(1) Current listed companies are indicated by (*).

Biography

Dr. Gerd Zettlmeissl, a German national, has more than thirty-five years of R&D and General Management leadership experience in the biopharmaceutical industry. Since 2012 he has served on the Board of Directors and Scientific and Strategic Advisory Boards of a number of non-profit organizations and biotech/vaccine companies. His most recent Supervisory Board appointments were: chairman of Themis (Austria) from 2015 to 2020, which was acquired by Merck Sharp and Dohme, between 2013 and 2023 chairman of Hilleman Laboratories (India, Singapore) and from 2021 to 2024 chairman of Minervax (Denmark). Since 2019 he has served as a member and chairman of the Board of Medigene (Germany). Dr. Zettlmeissl is the former CEO of Intercell, the vaccine biotech company which merged with Vivalis to form Valneva in 2013. Between 2001 and 2011, he supported Intercell's growth from an Austrian private start-up to a publicly listed international organization. During his time as CEO the company achieved the global regulatory approval and the launch of an innovative Japanese encephalitis vaccine, established and advanced a broad R&D portfolio for vaccines and executed major strategic pharma partnerships. Prior to joining Intercell, he was Managing Director of Chiron-Behring (Germany) and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron (USA) and Behringwerke (Germany). In 2010, Dr. Zettlmeissl was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Gerd Zettlmeissl authored and co-authored a wide range of patents and publications. He holds a doctoral degree in biochemistry of the University of Regensburg and completed a post-doctoral fellowship at the Institut Pasteur Paris in virology.



SHARE CAPITAL HELD BY THE BOARD MEMBERS WHOSE APPOINTMENT OR REAPPOINTMENT IS PROPOSED TO THE SHAREHOLDERS

Information as of May 31, 2026

Ms. Anne-Marie Graffin holds 39,000 ordinary shares of Valneva SE (or 0.02 % of the Company's share capital).

Mr. James Sulat holds 97,367 ordinary shares of Valneva SE (or 0.05 % of the Company's share capital).

Mr. James Connolly holds 20,000 ordinary shares of Valneva SE (or 0.01 % of the Company's share capital).

Mr. Thomas Lingelbach holds 412,273 ordinary shares of Valneva SE (or 0.22 % of the Company's share capital).

Ms. Kathrin Jansen does not hold any shares in the Company.



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.

2. GENERAL MANAGEMENT

The General Management is currently represented by Mr. Thomas Lingelbach, CEO (*Directeur Général*).

The CEO is a member of the Executive Committee established by the Company, which also includes Mr. Peter Bühler, Chief Financial Officer, Mr. Juan Carlos Jaramillo, Chief Medical Officer, Ms. Dipal Patel, Chief Commercial Officer, Mr. Vincent Dequenne, Chief Operating Officer, Ms. Petra Pesendorfer, Chief People Officer, Dr. Hanneke Schuitemaker, Chief Scientific Officer and Ms. Kendra Wergin, General Counsel & Corporate Secretary.



Mr. Vincent Dequenne

CHIEF OPERATING OFFICER
MEMBER OF THE EXECUTIVE
COMMITTEE



Ms. Kendra Wergin

*GENERAL COUNSEL & CORPORATE
SECRETARY*
MEMBER OF THE EXECUTIVE
COMMITTEE



Ms. Petra Pesendorfer

CHIEF PEOPLE OFFICER
MEMBER OF THE EXECUTIVE
COMMITTEE




**Dr. Hanneke
Schuitemaker, Ph.D.**

CHIEF SCIENTIFIC OFFICER
MEMBER OF THE EXECUTIVE
COMMITTEE



Ms. Dipal Patel

CHIEF COMMERCIAL OFFICER
MEMBER OF THE EXECUTIVE
COMMITTEE



**Mr. Juan Carlos
Jaramillo**

CHIEF MEDICAL OFFICER
MEMBER OF THE EXECUTIVE
COMMITTEE



Mr. Peter Bühler

CHIEF FINANCIAL OFFICER
MEMBER OF THE EXECUTIVE
COMMITTEE